Ahmed O. Kaseb, MD

home / authors / ahmed-o-kaseb-md

Articles

Ahmed O. Kaseb, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine,The University of Texas MD Anderson Cancer Center

Dr Kaseb on the Investigation of Adjuvant Atezolizumab and Bevacizumab in Early-Stage HCC

Ahmed O. Kaseb, MD
April 21st 2023

Ahmed O. Kaseb, MD, discusses the significance of results from the phase 3 IMbrave050 trial of adjuvant atezolizumab and bevacizumab for patients with early-stage hepatocellular carcinoma.

Read More

Dr. Kaseb on Safety Profile of Atezolizumab Plus Bevacizumab in HCC

Dr. Kaseb on Safety Profile of Atezolizumab Plus Bevacizumab in HCC

Ahmed O. Kaseb, MD
April 22nd 2020

Ahmed O. Kaseb, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

Read More

Dr. Kaseb on Research With Targeted Therapy in HCC

Dr. Kaseb on Research With Targeted Therapy in HCC

Ahmed O. Kaseb, MD
April 2nd 2020

Ahmed O. Kaseb, MD, a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses research with targeted therapy in hepatocellular carcinoma (HCC).

Read More

Dr. Kaseb on the Progression of HCC Research

Dr. Kaseb on the Progression of HCC Research

Ahmed O. Kaseb, MD
March 12th 2020

Ahmed O. Kaseb, MD, discusses the progression of therapy options for patients with hepatocellular carcinoma.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data